VYNE Therapeutics Inc. (VYNE) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.
The consensus price target is $5.75, representing an upside of 827.6% from the current price $0.62.
Analysts estimate Earnings Per Share (EPS) of $-0.96 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.93 vs est $-0.96 (beat +3.1%). 2025: actual $-0.62 vs est $-0.86 (beat +27.6%). Analyst accuracy: 79%.
VYNE Stock — 12-Month Price Forecast
$5.75
▲ +827.57% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for VYNE Therapeutics Inc., the price target is $5.75.
The average price target represents a +827.57% change from the last price of $0.62.
VYNE Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to VYNE Therapeutics Inc. in the past 3 months
EPS Estimates — VYNE
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.93
vs Est –$0.96
▲ 3.2% off
2025
Actual –$0.62
vs Est –$0.86
▲ 38.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — VYNE
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 6.5% off
2025
Actual $0.001B
vs Est $0.001B
▼ 5.3% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
